Materials
All the compounds used in the present study were commercially available, including 2-(N-(7-Nitrobenz-2-oxa-1,3-diazol-4-yl)Amino)-2-Deoxyglucose (2-NBDG, Invitrogen, USA, CID: 6711157), 2-deoxy-D-glocose (2DG, Invitrogen, USA, CID: 5287471), cytochalasin B (Shanghai Yuanye Bio-Technology Co., Ltd, China, CID: 5311281), metformin (Shanghai Yuanye Bio-Technology Co., Ltd, China, CID: 4091), Dapagliflozin (Shanghai Yuanye Bio-Technology Co., Ltd, China, CID: 9887712), , astragaloside IV (AST, Chengdu Mansit Bio-technology Co, Ltd, China, CID: 13943297), and cycloastragalol (CAG, Chengdu Mansit Bio-technology Co, Ltd, China, CID: 13943286). All detection kits were purchased from Nanjing Jiancheng Bioengineering Institute (Nanjing, China), and ELISA kits were obtained from Mlbio (USA). All other chemicals were of analytical grade and were obtained from Sigma (USA) and Merck (DE).